Recent advances in research on aspartate β-hydroxylase (ASPH) in pancreatic cancer: A brief update

• Published in: Biomolecules & biomedicine Vol. 18; no. 4; pp. 297 - 304
• Main Authors: Hou, Guofang, Xu, Boran, Bi, Yanghui, Wu, Chuanlin, Ru, Beibei, Sun, Bei, Bai, Xuewei
• Format: Journal Article
• Language: English
• Published: Bosnia and Herzegovina Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 05.11.2018
• Subjects: Animals; Antineoplastic Agents - pharmacology; Aspartate β-hydroxylase; Calcium-Binding Proteins - analysis; Calcium-Binding Proteins - chemistry; Calcium-Binding Proteins - metabolism; Humans; Membrane Proteins - analysis; Membrane Proteins - chemistry; Membrane Proteins - metabolism; Mitochondrial DNA; Mixed Function Oxygenases - analysis; Mixed Function Oxygenases - chemistry; Mixed Function Oxygenases - metabolism; Muscle Proteins - analysis; Muscle Proteins - chemistry; Muscle Proteins - metabolism; NK cell; Notch signaling pathway; pancreatic cancer; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - enzymology; Pancreatic Neoplasms - pathology; Review
• ISSN: 1512-8601; 2831-0896; 1840-4812; 2831-090X
• DOI: 10.17305/bjbms.2018.3539

Pancreatic cancer (PC) is a highly aggressive tumor, often difficult to diagnose and treat. Aspartate β-hydroxylase (ASPH) is a type II transmembrane protein and the member of α-ketoglutarate-dependent dioxygenase family, found to be overexpressed in different cancer types, including PC. ASPH appears to be involved in the regulation of proliferation, invasion and metastasis of PC cells through multiple signaling pathways, suggesting its role as a tumor biomarker and therapeutic target. In this review, we briefly summarize the possible mechanisms of action of ASPH in PC and recent progress in the therapeutic approaches targeting ASPH.